arginyl-glycyl-aspartic acid has been researched along with Corneal Angiogenesis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ge, H; Guan, L; Liu, H; Liu, P; Luo, X; Ni, S; Qi, D; Sun, Y; Tian, P; Xiao, N; Xiong, Y; Yin, X | 1 |
| Chang, CY; Chen, KH; Chen, ZY; Lin, FH; Liu, GS; Miyagawa, T; Tseng, CL; Wang, MC | 1 |
2 other study(ies) available for arginyl-glycyl-aspartic acid and Corneal Angiogenesis
| Article | Year |
|---|---|
A C-terminal fragment BIGH3 protein with an RGDRGD motif inhibits corneal neovascularization in vitro and in vivo.
Topics: Amino Acid Motifs; Angiogenesis Inhibitors; Animals; Apoptosis; Blood Vessels; Blotting, Western; Caspases; Cell Adhesion; Cell Movement; Cell Proliferation; Corneal Neovascularization; Disease Models, Animal; Extracellular Matrix Proteins; Flow Cytometry; Human Umbilical Vein Endothelial Cells; Integrin alphaVbeta3; Mutagenesis, Site-Directed; Oligopeptides; Peptide Fragments; Phosphatidylinositol 3-Kinases; Phosphorylation; Plasmids; Protein Folding; Proto-Oncogene Proteins c-akt; Rabbits; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A | 2013 |
Preparation of arginine-glycine-aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization.
Topics: Angiogenesis Inhibitors; Animals; Burns, Chemical; Catechin; Cell Survival; Corneal Neovascularization; Disease Models, Animal; Eye Burns; Human Umbilical Vein Endothelial Cells; Humans; Hyaluronic Acid; Integrin alphaVbeta3; Mice, Inbred C57BL; Molecular Targeted Therapy; Nanoparticles; Oligopeptides; Ophthalmic Solutions | 2017 |